• Reported GAAP EPS of -$0.02 up 90.48% YoY • Reported revenue of $65.84M up 40.53% YoY • Maravai LifeSciences increased its full year 2026 revenue guidance to $205M to $215M, up from prior. Adjusted EBITDA guidance was also raised to $30M to $32M for 2026.
Bullish
Maravai LifeSciences achieved 40.5% revenue growth to $65.8M in Q1 2026, returned to positive free cash flow, and saw TriLink base non-COVID revenue grow 15% year over year.
Bearish
Maravai faces uncertainty regarding high-volume CleanCap revenue, significant operating result fluctuations, and competition from larger companies developing potentially obsolete technologies, posing risks to future performance.